关于新辅助和辅助BRAF抑制剂在乳头瘤中的最新情况:系统性审查
Giulia Cossu1,2, Daniele S C Ramsay3,4, Roy T Daniel1
1Department of Neurosurgery, University Hospital of Lausanne and University of Lausanne, 1011 Lausanne, Switzerland.
Cancers
|October 26, 2024
概括
包括BRAF抑制剂 (BRAFi) 在内的向疗法显示,在 papillary craniopharyngiomas中显著减少瘤体积. 这些治疗提供了更好的结果和生活质量,将管理转向多学科方法.
科学领域:
- 神经瘤学神经瘤学
- 分子向疗法分子向疗法
- 喉瘤研究研究
背景情况:
- 在乳头膜瘤中BRAF突变使得有针对性的治疗开发成为可能.
- 向疗法旨在减少瘤生长,并最大限度地减少侵袭性治疗并发症.
- 本综述侧重于这些瘤的辅助和新辅助向疗法.
研究的目的:
- 系统地审查和总结针对乳头膜瘤的向治疗的数据.
- 评估BRAF抑制剂 (BRAFi) 作为辅助和新辅助治疗的疗效.
主要方法:
- 按照PRISMA指南进行系统审查.
- 在Scopus,Medline和Embase数据库中进行的搜索.
- 用于研究选择和数据提取的PICO方法.
主要成果:
- 分析了21项涉及53名患者的研究;26人接受了辅助BRAFi,25人接受了新辅助BRAFi.
- 常见的治疗方案:达布拉费尼布 (BRAFi) + 特拉美丁尼布 (MEK 抑制剂);显著减少瘤体积 (在 64% 的辅助病例中≥80%).
- 在大多数情况下,新辅助疗法表现出几乎完全的放射性反应.
结论:
- 向疗法在改善BRAF突变关节瘤的治疗结果方面发挥着关键作用.
- 随着有针对性的治疗方法的整合,多学科管理正在发展.
- 需要进一步的大规模试验来优化治疗方案和整合策略.
相关概念视频
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K